LSE:AZNPharmaceuticals
AstraZeneca’s Saphnelo Gains Ground In CLE As Autoimmune Catalysts Near
AstraZeneca’s Saphnelo has rapidly become physicians’ preferred biologic treatment for cutaneous lupus erythematosus, overtaking GSK’s Benlysta.
Clinicians are showing strong interest in Saphnelo across additional autoimmune indications, ahead of multiple pivotal trial readouts.
The news highlights AstraZeneca’s growing role in immunology alongside its established oncology presence.
AstraZeneca (LSE:AZN) is drawing fresh attention as Saphnelo gains traction in cutaneous lupus erythematosus,...